Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer
Farrow D, Vaughan T, Sweeney C, Gammon M, Chow W, Risch H, Stanford J, Hansten P, Mayne S, Schoenberg J, Rotterdam H, Ahsan H, West A, Dubrow R, Fraumeni J, Blot W. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes & Control 2000, 11: 231-238. PMID: 10782657, DOI: 10.1023/a:1008913828105.Peer-Reviewed Original ResearchConceptsGastroesophageal reflux diseaseNon-cardia gastric adenocarcinomaEsophageal adenocarcinomaGERD symptomsReflux diseaseH2 blockersGastric adenocarcinomaGastric cancerLarge population-based case-control studyPopulation-based case-control studyPopulation-based tumor registryEsophageal squamous cell carcinomaPerson structured interviewRisk of esophagealSquamous cell carcinomaEsophageal adenocarcinoma riskH2-receptor antagonistsCase-control studyGastric cardia adenocarcinomaRandom digit dialingLong-term usersTumor RegistryAdenocarcinoma riskDaily symptomsCell carcinoma